Accessibility Menu
Sunshine Biopharma logo

Sunshine Biopharma(NASDAQ) SBFM

Current Price$1.69
Market Cap$3.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year-100%
1 Year-89%
1 Month-19%
Sunshine Biopharma last closing stock price
MetricPriceDate
Last closeUSD 1.662026-07-24
Sunshine Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.78%USD 1.802026-07-17
1 month-18.63%USD 2.042026-06-24
3 month-83.4%USD 10.002026-04-24
Year to date-86.5%USD 12.302025-12-31
1 year-89.29%USD 15.502025-07-24
3 year-99.98%USD 9,220.002023-07-25
5 year-100%USD 464,000.002021-07-23
Since inception-100%USD 1,683,333,333.332009-10-30

Sunshine Biopharma Financials at a Glance

Market Cap

$3.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.49M

Net Income (TTM)

-$6.04M

EPS (TTM)

-$13.02

P/E Ratio

-0.13

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$1.69

Volume

219

Open

$1.69

Previous Close

$1.69

Daily Range

$1.69 - $1.70

52-Week Range

$1.66 - $24.30

Estimated Earnings Date

Aug 11, 2026

SBFM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sunshine Biopharma

Sunshine Biopharma makes generic medicines and nutritional supplements for everyday health needs. Its products help people manage chronic illnesses and support general wellness. The company also develops new drugs for cancer and viral infections.

Pills, Powders, and Potential: What’s in the Box?

  • Generic Prescription Drugs: 74 medicines for conditions like cancer, heart disease, and diabetes; sold to Canadian pharmacies (majority of revenue).
  • Nutritional Supplements: Over-the-counter tablets and vitamins, including Essential 9 and Calcium-Vitamin D, for general health support.
  • Proprietary Drug Development: Experimental drugs for cancer (K1.1 mRNA) and coronavirus (SBFM-PL4), not yet on the market.
  • Licensing and Distribution: Agreements with universities and partners to develop and distribute new drug technologies.

Growth Spurts and Strategic Moves

  • Acquired Nora Pharma and Sunshine Biopharma Canada in 2022 to expand into generics and supplements.
  • Signed licensing deals with University of Georgia and University of Arizona for antiviral drug research (2023-2024).
  • Launched 74 generic drugs in Canada by 2025; 17 more in pipeline for 2026.
  • Raised $1.83 million in April 2025 through a direct stock offering.

Why Sunshine Biopharma Stands Out (Without the Sunglasses)

The company combines commercial sales with in-house drug research, creating a diverse business model. Its Canadian focus leverages government drug programs and broad pharmacy access. Strategic licensing and a growing product pipeline support its position in the generic and specialty drug market.

Five Things You Need to Know

  • Revenue was $9.41 million in Q2 2025, up 1.2% from Q2 2024.
  • Net loss was $1.77 million in Q2 2025, compared to $0.49 million in Q2 2024.
  • Cash and cash equivalents totaled $10.31 million as of June 30, 2025.

Bottom Line

Sunshine Biopharma has evolved from a research-focused company to a diversified player in generics, supplements, and drug development. Its mix of commercial sales and innovation supports ongoing adaptation in a competitive healthcare market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

50

CEO

Steve N. Slilaty, PhD

Website

www.sunshinebiopharma.com

Headquarters

Fort Lauderdale, FL 33301, US

SBFM Financials

Key Financial Metrics (TTM)

Gross Margin

32.49%

Operating Margin

-12.90%

Net Income Margin

-17.01%

Return on Equity

-25.58%

Return on Capital

-18.78%

Return on Assets

-21.62%

Earnings Yield

-7.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.38M

Volume

219

Avg. Volume

1.64M

Financials (TTM)

Gross Profit

$11.53M

Operating Income

-$4.58M

EBITDA

-$5.63M

Operating Cash Flow

-$5.69M

Capital Expenditure

$180.78K

Free Cash Flow

-$5.51M

Cash & ST Invst.

$6.91M

Total Debt

$744.84K

Sunshine Biopharma Performance Analysis

Sunshine Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,345,6031802.4%
20232023-12-31USD 24,092,787454.4%
20242024-12-31USD 34,874,28344.7%
20252025-12-31USD 36,305,8914.1%
Sunshine Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.7%
Q32025-09-300.1%
Q42025-12-31-8.9%
Q12026-03-31-5.7%
Sunshine Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -35,234.40-99.8%
20232023-12-31USD -3,703.80-89.5%
20242024-12-31USD -73.16-98.0%
20252025-12-31USD -14.37-80.4%
Sunshine Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1672.7%
Q32025-09-3097.6%
Q42025-12-31-142.1%
Q12026-03-3145.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.09M

-9.1%

Gross Profit

$2.10M

-22.9%

Gross Margin

26.01%

N/A

Market Cap

$3.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$78.96K

N/A

Employees

50

N/A

Net Income

-$1.24M

-5.4%

EBITDA

-$1.17M

-1.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.91M

-15.6%

Total Debt

$744.84K

-20.4%

Accounts Receivable

$4.01M

+16.4%

Inventory

$13.17M

+11.1%

Long Term Debt

$535.61K

-25.8%

Short Term Debt

$209.23K

-2.2%

Return on Assets

-21.62%

N/A

Return on Invested Capital

-20.76%

N/A

Free Cash Flow

-$2.08M

-8.9%

Operating Cash Flow

-$2.07M

-22.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LUCYLucyd, Inc
$0.65-6.40%
ACXPAcurx Pharmaceuticals, Inc.
$1.42-2.07%
SNOASonoma Pharmaceuticals, Inc.
$1.14-1.72%
HCWBHCW Biologics Inc.
$2.50-13.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About SBFM

What is the current price of Sunshine Biopharma?

Sunshine Biopharma is trading at $1.69 per share.

What is the 52-week range for Sunshine Biopharma?

Over the past 52 weeks, Sunshine Biopharma has traded between $1.66 and $24.30.

How much debt does Sunshine Biopharma have?

As of the most recent reporting period, Sunshine Biopharma reported total debt of $744.84K.

How much cash does Sunshine Biopharma have on hand?

Sunshine Biopharma reported $6.91M in cash and cash equivalents in its most recent financial results.

What is Sunshine Biopharma’s dividend yield?

Sunshine Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services